This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

4. Leading National Epigenetic Therapy and Technology Markets 2013-2023

4.1 Leading National Markets for Epigenetic Therapies and Technologies 2011-2012

4.2 Leading National Markets: Revenue Forecasts 2013-2023

4.2.1 The Continued Dominance of Western Markets 2013-2023

4.3 The North American Market 2013-2023

4.3.1 The US: The World's Largest Market for Epigenetic Therapies and Technologies 2013-2023

4.3.2 Canada: Revenues 2013-2023

4.4 The European Market 2011-2012

4.4.1 Leading National Markets in Europe: Revenue Forecasts 2013-2023

4.4.2 Germany: Revenues 2013-2023

4.4.3 The UK: A Leading Market for Epigenetics Research

4.5 Japan: Recent Entry of the Epigenetic Therapies Market

4.6 Epigenetics in Emerging Markets

4.6.1 BRIC Nations: Rising Importance for Epigenetic Therapies and Technologies 2013-2023

5. Epigenetic Therapies Market 2013-2023

5.1 Changes to the Epigenetic Therapies Market 2013-20235.2 Vidaza: The First Epigenetic Therapy Approved5.2.1 Vidaza: Strong Revenue Growth 2004-20115.2.2 Development as a Combination Therapy to Drive Growth5.2.3 Vidaza: Revenue Forecast 2013-20235.3 Dacogen5.3.1 Revenue Performance 2004-20115.3.2 Approval in the EU in 2012 to Drive Revenue Growth5.3.3 Dacogen: Revenue Forecast 2013-20235.4 Zolinza5.4.1 Zolinza as a Potential Treatment for Multiple Myeloma5.4.2 Zolinza: Revenue Forecast 2013-20235.5 Istodax5.5.1 US PTCL Approval5.5.2 Istodax: Revenue Forecast 2013-20235.6 Rich Pipeline for HDAC Inhibitors in 20125.6.1 Belinostat: A Selective HDAC Inhibitor for PTCL5.6.2 Faridak for Velcade-Refractory Multiple Myeloma5.6.3 Entinostat (Syndax Pharmaceuticals)5.6.4 Resminostat (4SC)5.6.5 Pracinostat: The First Epigenetic Therapy Developed in Singapore5.6.6 Mocetinostat Has Been Tested in More Than 12 Clinical Trials5.6.7 Quisinostat (Centocor Research & Development)5.6.8 Rocilinostat (Acetylon Pharmaceuticals)5.6.9 CHR-3996 (Chroma Therapeutics) 5.6.10 Givinostat for Cancer, Autoimmune and Neurodegenerative Diseases5.6.11 SHP-141 (Shape Pharmaceuticals) 5.6.12 EVP-0334 (EnVivo Pharmaceuticals/MethylGene) 5.6.13 4SC-202 (4SC) 5.6.14 Tefinostat (Chroma Therapeutics) 5.6.15 CXD101 (Celleron Therapeutics) 5.6.16 Repligen: Epigenetic Therapies for Orphan Neurodegenerative Indications5.6.17 Abexinostat (Pharmacyclics/Servier)5.7 DNMT Inhibitor Pipeline 20125.7.1 SGI-110: A Second Generation DNMT Inhibitor5.8 Pipeline Treatments Targeting Other Epigenetic Enzymes 20125.8.1 EPZ-5676: The First Clinical-Stage HMT Inhibitor5.8.2 Oryzon Genomics: Targeting LSD15.8.3 Salarius Pharmaceuticals5.8.4 Resverlogix Advancing BET Protein Inhibitors5.9 MiRNA Therapy Pipeline 20125.9.1 Miravirsen (Santaris Pharma) is the Only Clinical-Stage miRNA Therapy5.9.2 MRX34 (Mirna Therapeutics)5.9.3 Regulus Therapeutics Is Collaborating with Big Pharma Players5.10 Leading Epigenetic Therapy Manufacturers and Developers 20125.10.1 Celgene: Market Leader 2011-20125.10.2 Eisai5.10.3 Merck & Co.5.10.4 TopoTarget: Assessing Drug Commercialisation Strategies5.10.5 Syndax Pharmaceuticals5.10.6 4SC5.10.7 Astex Pharmaceuticals is an Experienced Epigenetic Therapy Developer5.10.8 Curis is Developing Multi-Targeted Therapies5.10.9 CellCentric: Industry and Academic Collaboration for Drug Development5.10.10 Constellation Pharmaceuticals5.10.11 EpiTherapeutics5.10.12 Epizyme Has Signed Valuable Big Pharma Collaboration Agreements5.10.13 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders5.10.14 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer

6. Epigenetic Diagnostics Market 2013-2023

6.1 Development of the Epigenetic Diagnostics Market 2013-2023

5 of 12

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs